Medicis, Ranbaxy Forge Pact For Solodyn Generic

Law360, New York (May 6, 2010, 7:05 PM EDT) -- Medicis Pharmaceutical Corp. has reached consent and licensing agreements with Indian generics maker Ranbaxy Laboratories Inc., settling patent infringement claims against Ranbaxy over Medicis' oral acne drug Solodyn and enjoining Ranbaxy from continuing to market generics without a license.

Under the consent agreement, approved Thursday by Judge Joseph J. Farnan Jr. of the U.S. District Court for the District of Delaware, Ranbaxy acknowledged that Medicis' patent for Solodyn is valid and enforceable and admitted that products described in its disputed abbreviated new drug application are indeed...
To view the full article, register now.